Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NUP214
REST API REST API
Homo sapiens
NUP214 is differentially expressed in 289 experiments: 132 organism parts: testis, liver, ... (130 more);, 211 disease states: normal, chronic myelogenous leukemia, ... (209 more);, 103 cell types 401 cell lines 38 compound treatments and 72 other conditions.
Synonyms CAN, N214, CAIN, D9S46E
Orthologs ENSCING00000007890 (Ciona intestinalis)   Nup214 (Drosophila melanogaster)   NUP214 (Gallus gallus)   Nup214 (Mus musculus)   nup214 (Danio rerio)   NUP214 (Bos taurus)   Nup214 (Rattus norvegicus)   NUP100 (Saccharomyces cerevisiae)   NUP116 (Saccharomyces cerevisiae)   nup214 (Xenopus laevis)   NUP214 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transporter activity, cytosol, protein binding, protein import into nucleus, nucleocytoplasmic transporter activity, protein export from nucleus, RNA metabolic process, regulation of cell cycle, nucleus, mRNA export from nucleus, carbohydrate metabolic process, nuclear pore, transmembrane transport, nucleoplasm, protein transport, viral reproduction, glucose transport, mRNA metabolic process, regulation of glucose transport, hexose transport
InterPro Term WD40_repeat
UniProt Accession B7ZAV2, P35658, B4DZN4, Q5JUP9, E9PS86, E9PKD2, F5H131
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000126883
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
SNU1
2
E-MTAB-37, E-GEOD-15460
BT474
1
2
E-MTAB-62, E-MEXP-440, E-MTAB-37
GM18505
1
E-GEOD-19466
395 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (53 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18147, E-GEOD-18265
CD71+ early erythroid
2
E-TABM-145, E-AFMX-5
mononuclear
2
E-GEOD-13987, E-GEOD-26672
macrophage
2
3
E-GEOD-5099, E-GEOD-22373, E-GEOD-8286, E-GEOD-360, E-GEOD-3982 ... (5 experiments)
basal cell
1
E-GEOD-3998
hMOF over-expressed
1
E-GEOD-20193
97 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-MTAB-62, ... (52 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
3
E-MTAB-62, E-MTAB-37, E-GEOD-96
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
chronic myelogenous leukemia
1
3
E-GEOD-96, E-MTAB-37, E-MTAB-62, E-GEOD-5550
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
septic shock
2
E-GEOD-9692, E-GEOD-8121
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
205 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-1417, E-TABM-782, E-GEOD-697, ... (23 experiments)

Factor Value U/D Experiments
none
4
5
E-GEOD-5824, E-GEOD-412, E-MEXP-1601, E-TABM-868, E-GEOD-1740, ... (9 experiments)
mercaptopurine, methotrexate
1
E-GEOD-412
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
AMP
1
1
E-MEXP-2285
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
1,25-dihydroxyvitamin D3
2
1
E-GEOD-995
32 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
40
2
1
E-GEOD-3494
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-TABM-26, E-GEOD-2509, ... (8 experiments)

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-17385, E-MEXP-563

Genotype
studied in E-TABM-763, E-GEOD-22056, E-GEOD-17476, E-MEXP-421, E-GEOD-22593, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-20504, ... (9 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-6927, E-MEXP-561

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-958

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541

Processing time: 0.297 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM